ISPOR Midwest Regional Chapter

Chapter Activities



    Event: Midwest Regional Chapter Face-To-Face Meeting

    Date:  Monday, May 21, 2018 | 12:00-1:00 PM EDT

    Location: Baltimore Convention Center, Baltimore, MD, USA

    Room: TBD

    If you are attending the ISPOR Baltimore conference we encourage you to contact the Midwest Regional Chapter so we can get a head count. Please reply to the email you will receive or email to confirm your participation for an idea of head count.

    March 27, 2018 | 12:00 pm – 1:00 pm Central Time

    "Putting the Real-World back into Real-World Data: The Importance of Daily Assessments in Outcomes Research"


    When: March 27, 2018 | 12:00 PM - 1:00 PM CST



    Dr. Jason Allaire, PhD,  Associate Professor, North Carolina State University & Managing Partner, Generativity




    Growing research in the field of psychology has suggested that most behaviors exhibit significant short-term fluctuation or intraindividual variability. Consequently, taking a "snap shot" of an individual on a particular day fails to take into account how they were the day before or the day after. Variability in behavior has become not only an important predictor of outcomes but also an important outcome in its own right. This webinar will provided an overview of the theoretical rationale of and research design requirements associated with assessing intraindividual variability.  In addition, we will review recent intraindividual variability findings relevant to health outcomes research.  It will be argued that in order understand patient behavior, preferences, and outcomes you need to assess them every day or at least more than pre/post and certainly more than at a single occasion.



    Dr. Allaire is an associate professor in the Department of Psychology and North Carolina State University. He has authored over 45 publications in the fields of aging, cognition, and health disparities and has been awarded over 2.5 million in federal research funding. In addition, Dr. Allaire is founder and managing partner of Generativity Solutions Group a boutique HEOR consulting company focused on data analysis and research dissemination.


    Link To Register:


    "The Use of Patient Preference & Experience Data in FDA Regulatory Decision Making"


    When: Monday, January 29, 2018



    Carrie Kuehn, M.A., M.P.H., L.P.D, RAC, Senior Managing Scientist, Exponent, Inc.

    Jordana Schmier, M.A., Senior Managing Scientist, Exponent, Inc.



    This session will review the recent policy developments at FDA with regard to the use of patient preference and patient experience data in regulatory decision-making.  FDA has made it a priority to incorporate the patient voice in the review of new therapeutics, including drugs, biologics, and medical devices.  The agency is also encouraging the use of patient-based data in the development of new medical products and the design of clinical trials.  New guidance documents are now available, and FDA continues to hold frequent webinars, meetings, and workshops for the purpose of making clear their intentions and expectations for this new regulatory process.  However, there are many aspects of this regulatory process that remain yet to be determined. By the conclusion of this session, participants will have insight into how and why types of data can be gathered and how to present these findings to the appropriate audience. An analysis of the various stakeholders and goals of the patient engagement from each one’s perspective will help participants to interpret and frame their findings. The implications for FDA’s intense focus on patient-based data for the development and commercialization of new therapeutics will be discussed. In addition, recent experiences and lessons learned will be shared within the context of this rapidly evolving regulatory landscape.



    Dr. Carrie Kuehn is a regulatory consultant in Exponent’s Biomedical Engineering practice.  She is regulatory affairs certified (RAC) in U.S. FDA medical device and pharmaceutical regulatory affairs.  An epidemiologist by training, Dr. Kuehn has an extensive background in observational research in a variety of therapeutic areas.  Recently, Dr. Kuehn completed her Doctor of Law and Policy degree from Northeastern University where she focused her research on the emerging policy process of using patient-based data to inform FDA regulatory policy and decision-making.  Dr. Kuehn is a Lecturer in Northeastern University’s Regulatory Affairs Program and brings nearly 20 years of diverse training and experience to her consulting practice.


    Ms. Jordana Schmier has worked in the outcomes research field for more than 15 years. She has substantial expertise in quality of life assessment and instrument validation, outcomes research, modeling, and health economics. She has published and presented studies in medical areas including asthma and other respiratory conditions, oncology, infectious diseases, psychiatry, hypertension, and neurological and digestive diseases. Particular areas of interest include compliance with treatment, electronic data collection, and the use of novel methodologies in patient preference and utility assessment. Prior to joining Exponent, Ms. Schmier was a project manager at MEDTAP International, Inc., (now Evidera), where her work included quality of life and pharmacoeconomic study design and implementation as well as study and site management.


    Link To Archive:



    "The Importance of Critically Analyzing Assumptions in Pharmacoeconomic Models: A Case Study in Modeling a Comparison of Diabetes Treatments"

    Wednesday, December 13, 2017 | 12:00 – 1:00 PM CST


    Speaker: Harry J. Smolen, MS, President & CEO, Medical Decision Modeling Inc.


    This approximate 30-min presentation will address a recent pharmacoeconomic model publication and how a critical analysis of its basic model assumptions substantially alter the publication’s conclusions.



    Harry J. Smolen, MS, Medical Decision Modeling Inc., President and CEO since 1994, Mr. Smolen has successfully led hundreds of projects and grants including commercial modeling and evidenced-based projects with leading pharmaceutical, biotechnology, and medical diagnostic and device companies, as well as university medical research centers. He has been Principal Investigator for six National Institutes of Health (NIH) research and development grants. Each of these projects and grants involved the integration, analysis, and presentation of clinical, economic, and humanistic evidence to research and quantitatively analyze the benefits, risks, and costs of pharmaceuticals, biotechnologies, or medical devices. Mr. Smolen is the founder of MDM, and has over 20 years of experience applying computer simulation and other methodologies to analyzing the effectiveness and cost-effectiveness of healthcare interventions. He also has over 25 years of technical writing experience. Mr. Smolen is the Past President of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Chicago Region Chapter. He has been a study section member of the following review groups: NIH’s Healthcare Delivery and Methodologies; NIH’s Surgical Sciences, Biomedical Imaging, and Bioengineering; NIH’s Biomedical Computing and Health Informatics; and the US Army Medical Research and Materiel Command. He is an active member in ISPOR, as well as a frequent journal reviewer for Value in Health, Medical Decision Making, Pharmacoeconomics, and Health Policy. He earned an MS from Purdue University in Industrial Engineering with a concentration in healthcare computer simulation and a BS from the University of Southern California in Electrical Engineering with a specialization in computer systems. Mr. Smolen is pursuing (part-time) a PhD in Industrial Engineering with a concentration in Operations Research at Purdue University. In pursuit of his PhD, he completed the coursework required for a master’s degree in applied statistics.

    PowerPoint is included below as one of the attachments.



    "Savoring Life: A Comparison of Value Frameworks"


    Date: November 15, 2017 | 12:00 – 1:00 PM CST


    Speaker:   Dr. Daniel Touchette, PharmD, MA, Associate Professor, University of Illinois at Chicago College of Pharmacy


    Time:  12:00 pm – 1:00 pm Central Time


    Discussion on estimating the costs and benefits of pharmaceuticals, along with a summary and critique of current methods and frameworks for assessing value.


    Daniel R. Touchette, PharmD, MA, FCCP

    Daniel Touchette is Associate Professor in the Department of Pharmacy Systems Outcomes and Policy. Dr. Touchette received his BS in Pharmacy from the University of Manitoba, and his PharmD and Master of Economics degrees from Wayne State University in Detroit. He also completed a fellowship in pharmacoeconomics and outcomes research at Wayne State. Dr. Touchette's primary research interests are in pharmacoeconomics and outcomes research. In particular he is interested in assessing the effectiveness and cost-effectiveness of clinical pharmacist and other health practitioner services, developing and assessing methods for improving adherence to medications, and evaluating the cost-effectiveness of pharmaceuticals. Dr. Touchette has numerous grants and over 50 publications evaluating clinical services, economic evaluations of clinical services and pharmaceuticals, and the impact of formulary and benefit designs on medication use.

    Event Archive Link:  




    “Methods for population-adjusted indirect treatment comparison (ITC) of time-to-event outcomes”


    Date: Wednesday, October 18, 2017 | 12:00 – 1:00 PM CST


    Speaker:  Vardhaman Patel, MS, PhD, Scientist, Modeling & Meta-Analysis, Pharmerit International


    The presentation will cover: (a) population-adjusted ITC methods such as matching-adjusted indirect treatment comparisons (MAIC) and simulated treatment comparisons (STC); and (b) digitization of time-to-event curves from trial publications to conduct population-adjusted ITC.



    Vardhaman Patel, PhD, is a scientist in the Modeling and Meta-Analysis group with Pharmerit International (Bethesda, MD). He received a PhD degree with a major in pharmacoeconomics and minor in pharmacoepidemiology from the University of Illinois at Chicago (UIC). Prior to joining Pharmerit, Vardhaman worked at Eisai Inc., where he extensively developed and adapted core/global budget impact and cost-effectiveness models for countries in Europe and Asia. In addition, he conducted meta-analyses and indirect treatment comparisons, developed the economic sections of dossiers and BaseCase interfaces for economic models. Vardhaman is experienced in the design and execution of medical chart reviews, systematic literature reviews, research proposals, and observational studies using claims data. He has co-authored several publications and peer reviewed manuscripts. His prior areas of experience include soft tissue sarcoma, epilepsy, acute coronary syndrome, thrombocytopenia, thrombosis and atopic dermatitis. Vardhaman is passionate about enhancing patients’ access to medicines by demonstrating the product value to payers using economic models.


    Link To Archive:




    “Precision medicine and its applications in HTA and clinical decision making”.


    Date: Thursday, September 28, 2017 | 12:00 – 1:00 PM CST


    Speaker: Eric Q. Wu, PhD, Managing Principal, Analysis Group, Inc.



    We will discuss how rich clinical, economic, and genomic data can be used to identify best treatment target population, and the most appropriate treatment for each individual. We will also give examples to illustrate how the application of these methods can help with HTA negotiation and improve clinical practice.



    Dr. Wu is a health economist specializing in health economics, outcomes, and market access issues related to pharmaceuticals and biologics. He has broad experience consulting to pharmaceutical and device companies, payers, and government agencies in North America, Europe, and Asia. Dr. Wu has extensive experience in the development of health economics and outcomes research strategy, analysis of medical claims and clinical trial data, patient chart review, patient surveys and physician surveys, and economic


    Event Archive:




    “Collection of patient-entered data as part of clinical care:  Experience in the implementation and utilization at Cleveland Clinic”


    Date: June 29, 2017 | 12:00 – 1:00 PM CST


    Speaker:   Dr. Irene Katzan, MD, MS, ‎Director, Neurological Institute Center for Outcomes Research and Evaluation, Cleveland Clinic


    Patient-reported outcomes are taking an increasingly important role in medical care.  In addition to their use at the patient level to monitor progress of individual patients, patient-reported data at an aggregate level have significant theoretical potential for use in research, quality initiatives and operational analyses.  Systematic collection of patient-reported information as part of routine care presents several challenges.  This presentation will outline the Cleveland Clinic experience with the collection and use of patient-reported information.


    Key Learnings & Takeaways:

    At the end of the session participants will be able to:

    • Discuss reasons for the increased use of patient-reported data in healthcare
    • Describe how patient-reported outcomes data can be integrated into ambulatory clinical workflows· List examples of how patient-reported data aid in clinical care
    • Identify opportunities to use patient-reported data to generate new knowledge


    Irene Katzan, MD, MS is a neurologist and Director of the Cleveland Clinic Neurological Institute Center for Outcomes Research and Evaluation. She has a background in evaluating the outcomes of care in neurological diseases and in modifying systems to optimize patient management across healthcare venues. She is also the Medical Director for Patient-Entered Data at Cleveland Clinic and led the development and implementation of the patient-entered data initiative to collect patient-reported outcomes information at the point of care. Currently health status information is collected electronically in over 100,000 clinical encounters each month at Cleveland Clinic.


    Link To Archive:   





    “Social support is a moderator in the relationship between comorbidity medication adherence and Healthy Days for patients with metastatic cancer.”

    Thursday, March 9, 2017 | 12:00 – 1:00 PM CST


    Dana Drzayich Antol, MS –  Research Consultant

    Comprehensive Health Insights, Humana, Inc., Louisville, KY              

    Adrianne Waldman Casebeer, MPP, MS, PhD – Research Lead,

    Comprehensive Health Insights, Humana, Inc., Louisville, KY


    Brief Description:

    A prospective survey design was used to understand the relationship between comorbidity medication adherence and health-related quality of life among patients with metastatic breast, lung or colorectal cancer and at least one comorbid condition who recently underwent anti-cancer treatment.  Health-related quality of life was assessed using the CDC's Healthy Days measure which captures the total number of physical and mental unhealthy days in the prior month.


    Key Learnings & Takeaways:

    • Patients with low comorbidity medication adherence experienced more unhealthy days than those with high comorbidity medication adherence.
    • The increase in unhealthy days attributed to low comorbidity medication adherence is further amplified by low social support.
    • This finding suggests that a greater importance should be placed on patients' social and caregiver resources including encouraging engagement with cancer support programs.




    Dana Drzayich Antol, MS


    Ms. Drzayich Antol is a Research Consultant with Comprehensive Health Insights.  She earned a Master of Science degree in Epidemiology and Biostatistics from Case Western Reserve University.  Ms. Drzayich Antol has over twenty years experience in health care research. She has designed and analyzed research studies to quantify the effectiveness of disease management and quality improvement interventions using administrative medical claims data.  She has managed and analyzed international clinical drug trials focused on improving tuberculosis treatment and worked on the development of a medical devise intended to measure inter-arterial blood gas.  Her research experience has included study design, project management, advanced statistical methods, regulatory compliance and report development to inform business decision making.  Ms. Drzayich Antol has authored and co-authored articles in peer-reviewed publications.

    Adrianne Casebeer, MPP, MS, PhD

    Dr. Adrianne Casebeer is a Research Lead with Comprehensive Health Insights.  She provides research support to a variety of initiatives for Comprehensive Health Insight’s external clients.   Dr. Casebeer has conducted health services and outcomes research with multi-disciplinary teams for government, non-profits and clinical trials.  She earned her Doctorate in Public Affairs from the University of Colorado, a Masters in Public Policy from Georgetown University and a Masters of Science in Management and Decision Making from the University of Arizona at Tucson.  She has worked for the Division of Cardiac Research, Denver Veterans Affairs Medical Center; The Colorado Prevention Center; and the South Carolina State Budget and Control Board. Dr. Casebeer is an adjunct faculty member at the Graduate School of Health Administration and Policy at George Mason University.  She has co-authored regular reports for governmental oversight bodies, abstracts and peer-reviewed publications.




    "Is all adherence created equal? A study of the impact of direction of change in adherence to therapy and magnitude of comorbidity on medical spending in patients with three chronic conditions"

    February 7, 2017 | 12:00 – 1:00 PM CST


    Speaker: Steven Kymes, Ph.D., Director, U.S. Health Economics and Outcomes Research, Lundbeck


    Brief Description:

    Adherence to medical therapy has long been recognized as a major public health problem, and there are numerous studies to demonstrate that patients who are adherent to therapy have better health and economic outcomes than patients who are not. However, these cost studies have been traditionally been conducted in a cross-sectional fashion comparing medical spending of those who are adherent to medication to those who are not in the same period---thus there is limited generalizability of these studies to interventions implemented to improve medication adherence. We examined the impact of change in adherence behavior over two consecutive years on medical spending in a cohort of commercially insured patients with 1) Diabetes; 2) Hypertension; or 3) Hypercholesterolemia (high cholesterol).


    Key Learnings & Takeaways:

    • Participants will gain an understanding of that whether a patient is becoming adherent or becoming non-adherent affects the magnitude of savings (or extra spending) experienced within the health system.
    • They will also learn that the magnitude of these savings (or excess spending) is dramatically impacted by the degree of comorbidity the patient is bearing.
    • Together these factors have important implications for the targeting of programs intended to improve medication adherence.



    Dr. Steven Kymes is the Director of U.S. HEOR at Lundbeck, an international pharmaceutical company providing therapies for treatment of diseases of the central nervous system. He received his doctorate in health services research from the Saint Louis University School of Public Health in 2001. After graduation, he joined the faculty of the Washington University School of Medicine (St. Louis) where he was the founding director of the Center for Economic Evaluation in Medicine. He left academic life in 2012 to join CVS Health as an Executive Advisor in their Enterprise Analytics group. There he led development predictive metrics for targeting of pharmacy interventions and worked to improve estimates of the value of improved medication adherence. He left CVS in early 2016 to join Lundbeck.

    Use This Link To Access The Archive:



    Midwest Regional Chapter - Face-to-Face Meeting

    “Qualitative Research: What It Can and Cannot Do”


    Date: November 3, 2016 | 6:30 pm – 8:30 pm Central Time


    Speaker:  Dr. Lisa Sharp, ‎University of Illinois at Chicago

    Location:  University of Illinois at Chicago, College of Pharmacy, 833 S. Wood Street, Chicago, IL  60604 Room: PHARM 212/216



    • To de-mystify qualitative research methods, and discuss how it meets scientific rigor, including some real examples of applications
    • Following the seminar there will be a career panel discussion for students featuring panel members from industry, academia, and consulting
    • There will also be an opportunity for networking for all attendees.


    "The Other Purchaser: Exploring Employer Sponsored Care Metrics and Perspectives of Chronic Care"


    Date: January 27, 2016 | 12:00 – 1:00 PM CST



    SpeakerF. Randy Vogenburg, PhD, Partner, Access Market Intelligence, and The National Institute of Collaborative Care


    RSVP: Aki Shiozawa at by COB Friday, January 15, 2016 (You must RSVP to obtain the WebEx Link)


    The new era of health care requires a multi-stakeholder understanding of more than one perspective of decision-maker or purchaser. Understanding what employers as purchasers of health care want to know about biologic and specialty drugs along with corresponding devices or diagnostic products has emerged in importance along with patient-focused analyses.  Determining data gaps and needed insights by employers as plan sponsors around utilization of these drugs, devices or diagnostics is of interest now to providers, manufacturers and third party payers.  What can be learned from employer determined shortfalls and innovations around providing chronic care will be shared from a multi-year employer initiative.  In addition, contrasting public sector versus private sector market segments and multiple stakeholder views on medical or pharmacy benefit coverage will be discussed.


    “Designing Clinical Tools Using Big Data: An Example on Depression and Health Care Databases”

    Date: December 9, 2015 | 12:00 – 1:00 PM CST


    Speaker: Clement Francois, Vice President, US HEOR, Lundbeck LLC



    Health care databases are an excellent source for health and drug-related data, but there is a shortage of clinical information used to evaluate the severity of the disease. This is particularly true in depression and other mental health diseases, as there are no tests or biomarkers. Using data mining techniques and Clinical Practice research Datalink (CPRD), we created an index which estimates the health state of a depressed patient at a specific point in time on a continuous scale ranging from the worst possible to the best possible state. This presentation will provide a brief overview of the development of the index and preliminary results, and allow for a discussion and sharing of experiences in the field of database and data mining.

    “Market Access in US & Europe”


    Date: December 1, 2015 (Tuesday) | 3:00–6:00 pm Central Time


    Speaker: Professor Mondher Toumi, University of Aix-Marseille & CEO at Creativ-ceutical


    Course Description:

    Unlike marketing authorization for pharmaceuticals, mainly regulated at the European level by EMA, pricing and reimbursement decisions in Europe are managed by individual Member States. Health care services are generally covered by a single public health insurer operating under the Ministry of Health supervision. As a monopoly buyer, this situation provides a leading position for the public health insurer to set reimbursement conditions. Therefore, based on each country’s set of regulations, processes, and values, wide variations exist in pricing and reimbursement decisions of pharmaceuticals. Using up-to-date governmental regulation sources this course will discuss health technology decision-making processes for reimbursement decisions for pharmaceuticals in France, Germany, Hungary, Italy, Poland, Spain, Sweden, and the UK. The course will describe these reimbursement systems, as well as compare, and bring into contrast their key characteristics. We will along the whole course put the European findings in perspective with the US system.


    Course learning objectives:

    • To provide an overview of the European reimbursement policies;
    • To identify and generate payers’ evidence requirements;
    • To understand the strategic considerations for a successful reimbursement application;
    • To put EU system in perspective with the US market access conditions.


    After the completion of this course, participants will be able to:

        1. Understand the current context of reimbursement of pharmaceuticals in Europe;

        2. Understand the diversity of approaches of reimbursement decisions across Europe;

        3. Understand the requirements for successful payers coverage;

        4. Understand the importance to closely monitor the reimbursement decisions to anticipate the changes in decisions and requirements overtime.

    2017.12.13 mdm ISPOR Midwest Regional Chapter presentation

About Chapter

Chapter Leadership
PresidentCynthia Holmes, MSP, PharmD
President-ElectGebra Cuyún Carter , MPH, PhD
Past PresidentLesley-Ann Miller, MS, PhD, MBA
Secretary/TreasurerAnnette Champion, MBA
Director of ProgrammingVanessa Perez, MS, PhD
Director of CommunicationsNancy Kadish, MS
Links / Resources

Established June 2006
Midwest Regional Chapter members meet at the ISPOR 18th Annual International Meeting, May 2013 ~ New Orleans, LA, USA
Midwest Regional Chapter members meet at the ISPOR 18th Annual International Meeting, May 2013 ~ New Orleans, LA, USA
ISPOR 18th Annual International Meeting, May 2013 ~ New Orleans, LA, USA
ISPOR 18th Annual International Meeting, May 2013 ~ New Orleans, LA, USA
May, 2015, Philadelphia, USA. Midwest Regional Chapter Meeting, ISPOR 20th Annula International Meeting
May, 2015, Philadelphia, USA. Midwest Regional Chapter Meeting, ISPOR 20th Annula International Meeting

ISPOR Regional Chapters Index